Stay updated on Daratumumab in High-Risk MGUS & Low-Risk Smoldering Clinical Trial

Sign up to get notified when there's something new on the Daratumumab in High-Risk MGUS & Low-Risk Smoldering Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Daratumumab in High-Risk MGUS & Low-Risk Smoldering Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    No Change Detected
  3. Check
    20 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-05-01T05:49:20.000Z thumbnail image
  4. Check
    27 days ago
    No Change Detected
  5. Check
    34 days ago
    Change Detected
    Summary
    The page has undergone significant updates, including the removal of detailed information about a clinical trial for Daratumumab, a drug for treating Monoclonal Gammopathy and Smoldering Multiple Myeloma, and the addition of new collaborators and a revision number.
    Difference
    45%
    Check dated 2025-04-16T14:43:15.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    The web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to March 5, 2025.
    Difference
    0.2%
    Check dated 2025-04-09T09:50:04.000Z thumbnail image
  7. Check
    49 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.2 to version 2.14.3.
    Difference
    0.1%
    Check dated 2025-04-01T23:33:07.000Z thumbnail image
  8. Check
    71 days ago
    Change Detected
    Summary
    The page has updated its last update date to March 2025, reflecting a shift in the timeline for content relevance. Additionally, previous update dates from February 2024 have been removed.
    Difference
    0.8%
    Check dated 2025-03-11T04:46:58.000Z thumbnail image
  9. Check
    85 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    1%
    Check dated 2025-02-24T21:23:40.000Z thumbnail image

Stay in the know with updates to Daratumumab in High-Risk MGUS & Low-Risk Smoldering Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Daratumumab in High-Risk MGUS & Low-Risk Smoldering Clinical Trial page.